Skip to main content

Table 1 Patient demographics and characteristics

From: Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

 

Overall

H101

Control

P-Value

Overall Survival(%)

Median survival(mo)

Univariate

Multivariate

 

1-yr

2-yr

 

P-Value

ExpB (Hazard Ratio ,95 % CI)

P-Value

Gender

   

0.305

   

0.302

  

 Male

159

81

78

 

67

52

13.0

   

 Female

16

6

10

 

60

30

11.2

   

Age

   

0.948

   

0.100

  

 Median

55.0

55.0

54.5

       

  < 60

114

59

55

 

68

49

12.5

   

  ≥ 60

61

28

33

 

68

56

13.0

   

Alpha-foetoprotein(ng/ml)

   

0.316

      
 

307.2

269.1

307.2

       

Alpha-foetoprotein(ng/ml)

   

0.947

   

0.06

1.669(1.178–2.366)

0.004

  ≤ 20

53(30.1 %)

27(30.7)

26(29.5)

 

89

81

17.6

   

 20–400

42(23.9 %)

20(22.7)

22(25.0)

 

60

45

13.9

   

  ≥ 400

80(45.5 %)

40(45.5)

40(45.5)

 

52

32

9.1

   

Child Pugh grade

   

0.820

   

0.007

2.132(1.138–3.995)

0.018

 A

154(88.0 %)

76(87.3 %)

78(88.6 %)

 

70

55

13.3

   

 B

21(12.0 %)

11(12.6)

10(11.3)

 

38

25

7.7

   

ALB(g/L)

   

0.228

   

0.412

  

 Median

40.0

39.6

40.2

       

  ≥ 35

131

61

70

0.166

62

50

11.7

   

  < 35

44

26

18

 

67

52

13.3

   

Tbil(U/L)

   

0.386

   

0.003

  

 Median

16.4

16.1

16.8

       

  < 20

119

61

58

0.628

75

56

13.7

   

  ≥ 20

56

26

30

 

48

40

8.0

   

Virus infection

   

0.970

   

0.101

  

 none

15

7

8

 

88

66

13.6

   

 HBV

158

79

79

 

63

51

12.6

   

 HCV

2

1

1

 

50

0

13.9

   

Platelet count (10E9/L)

   

0.630

   

0.676

  

 Median

167.0

179.2

154.5

       

  < 100

31

11

20

0.112

63

46

12.2

 

0.330(0.141–0.773)

0.011

  ≥ 100

144

76

68

 

67

53

12.8

   

No. of tumours

   

1.000

   

<0.001

2.024(1.127–3.633)

0.018

  ≤ 3

127

69

70

 

74

57

13.7

   

  > 3

36

18

18

 

38

30

7.6

   

Tumour size (cm)

   

0.730

   

0.028

2.936(1.297–6.650)

0.010

  ≤ 5

45

21

24

 

91

75

18.1

   

  > 5

130

66

64

 

56

42

9.8

   

Anti-HBV therapy

   

0.197

   

0.424

  

 Yes

56

32

24

 

60

54

13.3

   

 No

119

55

64

 

69

51

9.65

   

H101

   

0.046

   

0.042

0.593(0.353–0.995)

0.048

 Yes

87

87

0

 

69

60

12.8

   

 No

88

0

88

 

60

44

11.6

   

 BCLC stage

   

0.453

   

0.001

2.168(1.322–3.557)

0.002

 A3

1

0

1

       

 A4

17

10

7

 

94

94

17.0

   

 B

108

50

58

 

72

56

12.96

   

 C

49

27

22

 

52

23

6.96

   
  1. AFP alpha fetoprotein, ALB serum albumin, HBV hepatitis B virus, HCV hepatitis C virus, TBIL total bilirubin, PVT portal vein thrombosis